Q1 2026 EPS Estimates for Halozyme Therapeutics, Inc. Raised by Zacks Research (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Zacks Research increased their Q1 2026 EPS estimates for shares of Halozyme Therapeutics in a report released on Monday, September 23rd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $1.41 for the quarter, up from their previous forecast of $1.40. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.71 per share.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same period last year, the firm earned $0.68 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 4.7% on a year-over-year basis.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, September 13th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. The Goldman Sachs Group lifted their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Finally, Benchmark reiterated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $56.97 on Thursday. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. Halozyme Therapeutics has a one year low of $32.83 and a one year high of $65.53. The company has a 50-day simple moving average of $58.67 and a 200-day simple moving average of $49.68. The stock has a market capitalization of $7.25 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 0.56 and a beta of 1.28.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Janney Montgomery Scott LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth $473,000. Norges Bank acquired a new position in Halozyme Therapeutics during the 4th quarter valued at about $44,935,000. Corient Private Wealth LLC increased its stake in Halozyme Therapeutics by 17.2% during the 4th quarter. Corient Private Wealth LLC now owns 21,881 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 3,206 shares during the period. Nations Financial Group Inc. IA ADV bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $236,000. Finally, Hsbc Holdings PLC lifted its stake in shares of Halozyme Therapeutics by 27.7% in the 4th quarter. Hsbc Holdings PLC now owns 100,101 shares of the biopharmaceutical company’s stock worth $3,698,000 after acquiring an additional 21,697 shares during the period. 97.79% of the stock is owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at $834,836.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total transaction of $557,200.00. Following the completion of the transaction, the director now directly owns 89,755 shares of the company’s stock, valued at approximately $5,001,148.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at approximately $834,836.40. The disclosure for this sale can be found here. Insiders sold a total of 84,881 shares of company stock valued at $4,932,284 in the last quarter. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.